We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Early Treatment Effective for Lung Disease Side-Effects of New Cancer Drug
News

Early Treatment Effective for Lung Disease Side-Effects of New Cancer Drug

Early Treatment Effective for Lung Disease Side-Effects of New Cancer Drug
News

Early Treatment Effective for Lung Disease Side-Effects of New Cancer Drug

Credit: kalhh/ Pixabay
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Early Treatment Effective for Lung Disease Side-Effects of New Cancer Drug "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lung disease caused by a new drug for cancers—including metastatic or advanced breast cancer—can be effectively treated using approaches that focus on early detection and prompt management, according to a study published in ESMO Open on August 11, 2022.


Using data from nine clinical trials, this study provides one of the most comprehensive analyses of interstitial lung disease diagnosis and treatment in patients who received an antibody drug conjugate known as T-DXd, from a class of drugs designed as a targeted therapy for treating cancers.


The retrospective review examined 1,150 heavily pre-treated patients with breast, lung, gastric, colorectal or other cancers across nine studies treated with T-DXd, also known as ENHERTU®.


“Interstitial lung disease (ILD) is a known risk factor in patients treated with antibody drug conjugates for cancer,” said senior author Charles Powell, MD, MBA, Janice and Coleman Rabin Professor of Medicine and Chief of Pulmonary, Critical Care and Sleep Medicine at the Icahn School of Medicine at Mount Sinai. “Using learnings from the early clinical trials experience, physician education and patient management protocols were revised and disseminated by the study sponsors. More recent trial data in earlier lines of therapy has demonstrated lower rates of ILD events, suggesting close monitoring and proactive management of ILD/pneumonitis is warranted for all patients.”


The researchers reviewed data from four phase 1 and five phase 2 studies of T-DXd, where patients received varying doses of the cancer therapy every three weeks. The research team also reviewed data from an independent clinical adjudication committee, chaired by Dr. Powell, which reviewed clinical information and chest CT imaging on all clinical trial patients with suspected drug-related interstitial lung disease, which can lead to lung fibrosis.   


In patients who were previously heavily treated with other cancer therapies, the analysis found that 15.4 percent (grade 1 or 2, 77.4%; grade 5, 2.2%) experienced interstitial lung disease—with low-grade symptoms typically occurring within the first 12 months—after treatment with T-DXd.


Interstitial lung disease is a known risk of several cancer therapies, including T-DXd, which can be severe, life-threatening, or fatal. These study results suggest that close monitoring and proactive management may reduce the risk of ILD, and patient awareness and ongoing education can aid in early detection.


Reference: Powell CA, Modi S, Iwata H, et al. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022;7(4):100554. doi: 10.1016/j.esmoop.2022.100554


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

 
Advertisement